English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 May 2023, 07:00 HKT/SGT
Share:
    

Source: CellOxess Biotechnology
Fertilix Proven Effective in Blocking Damage From Low-Dose Exposure to Chemicals Commonly Found in Plastic Consumer Products

CLERMONT-FERRAND, FRANCE, May 19, 2023 - (ACN Newswire) - According to a recent study by Universite Clermont Auvergne researchers, exposure to chemical additives and building blocks commonly used in everyday plastic products, even in low doses, can cause significant damage to the genetic material carried by sperm cells.

Fertilix(R) logo

The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF. These chemicals have long been linked to lowering male fertility, but the novelty of this study was in evaluating doses that were previously considered safe or inconsequential for consumers. While researchers found no appreciable effect on general semen parameters typically examined in fertility clinics such as sperm counts and motility, significant oxidation and decompaction of DNA structure in sperm cells were observed. This is concerning because damage to paternal genetic material can expose the female partner to higher risk of pregnancy loss and potentially impact the health of the offspring. Interestingly, the study also showed that co-administration with micronutrient supplement Fertilix(R) significantly blocked the damaging effects of these chemicals on sperm DNA.

Given that microplastics are found everywhere in our surroundings, these findings underscore the importance of greater public awareness and the urgency for the plastic industry to replace such substances with biodegradable or natural alternatives. Furthermore, fertility experts counseling couples ahead of natural or assisted conception should advocate for preconceptual supplementation and possible lifestyle modifications that may mitigate the impact of environmental pollutants.

This study is now available with open-access in Antioxidants, a premier journal in antioxidant research, and can be downloaded here. https://www.mdpi.com/2076-3921/12/5/1046 CellOxess Biotechnology, the designer and manufacturer of Fertilix(R) formulations, will present the full results of this study at the European Society of Human Reproduction and Embryology (ESHRE) annual meeting this June in Copenhagen, Denmark.

Contact Information
Frances Gallagher, MPH
Marketing & Communications Coordinator
contact@celloxess.com

Topic: Press release summary
Source: CellOxess Biotechnology

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Fujitsu, Resona Bank and Saitama Resona Bank launch new web service to simplify home-buying process  
Wednesday, January 15, 2025 12:13:00 PM
TANAKA's Group Company EEJA to Exhibit at 39th NEPCON JAPAN  
Wednesday, January 15, 2025 10:00:00 AM
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease  
Wednesday, January 15, 2025 9:03:00 AM
Bedding Industries of America Unveils Glacier: The Ultimate Hybrid Cooling Mattress  
Jan 14, 2025 23:42 HKT/SGT
18th Asian Financial Forum wraps up successfully  
Tuesday, January 14, 2025 10:39:00 PM
18th Asian Financial Forum officially kicks off today  
Jan 14, 2025 22:38 HKT/SGT
Swiss WEB3FEST Winter Edition 2025  
Jan 14, 2025 11:01 HKT/SGT
One-Hour Payouts: Hola Prime Solves Prop Trading's Biggest Problem  
Jan 14, 2025 10:00 HKT/SGT
Investing in Tomorrow: Winvest Group Opens Up Metaverse Opportunities  
Jan 13, 2025 23:00 HKT/SGT
AI and Big Data Expo Global Countdown: Less than 4 weeks to go!  
Jan 13, 2025 22:36 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575